This study aims to investigate the role of inflammation in carpal tunnel syndrome (CTS) using a prospective cohort study design. The study will involve a sample of at least 50 individuals with CTS who will undergo a comprehensive clinical and biochemical evaluation to assess the role of inflammation in CTS. The primary outcome measures include inflammatory markers, such as C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), as well as clinical measures of CTS severity. Data will be analyzed using regression analysis to determine the relationship between inflammation and CTS. The study is expected to provide information on the role of inflammation in CTS and inform the choice of drug and concentration for transdermal drug administration.

Inclusion Criteria:

• Individuals aged 18 years or older
• Diagnosis of carpal tunnel syndrome based on clinical symptoms and nerve conduction studies
• Willingness and ability to provide informed consent to participate in the study
• Willingness and ability to comply with study procedures and follow-up visits

Exclusion Criteria:

• Presence of other neurological conditions that may affect nerve function in the upper extremities
• Use of medications that may affect inflammation or carpal tunnel syndrome severity
• History of previous carpal tunnel release surgery on the affected wrist
• Inability to comply with study procedures or follow-up visits
• Pregnancy or breastfeeding

The study population will be recruited from a single center and will include at least 50 individuals with CTS. The population may include individuals of all ages, but the study will likely focus on middle-aged and older adults, as CTS is more common in this population.

The study population will be diverse in terms of gender and race/ethnicity to ensure that the study findings are generalizable to a broader population.

The individual participant data (IPD) collected during this study will be available upon reasonable request. Requests for access to the data should be submitted via email to mohamed.elmeligie@acu.edu.eg. All requests will be reviewed by the study investigators to ensure that they are reasonable and consistent with the ethical principles of the study. Access to the data will be granted in compliance with applicable laws and regulations, and with appropriate safeguards to protect the privacy and confidentiality of study participants.

After finishing the trial and up to 1 year.

via email to mohamed.elmeligie@acu.edu.eg